This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stryker Recalls Sage Unit Products, Guidance Takes a Hit
by Zacks Equity Research
Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.
Ecolab Sales Solid Amid Escalating Delivered Product Costs
by Zacks Equity Research
Ecolab's (ECL) strong sales growth will continue to be aided by new business gains, better pricing and product innovation. However, higher delivered product costs remain a concern.
Top Stock Reports for Duke Energy, Stryker & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Duke Energy (DUK), Stryker (SYK) and Sanofi (SNY).
Bruker Launches D8 VENTURE BIOTOOLS for Home Laboratory
by Zacks Equity Research
Bruker's (BRKR) D8 VENTURE BIOTOOLS for laboratory macromolecular crystallography has some latest features in terms of source, detector and sample handling technology.
PAREXEL Ties Up With Osaka International Cancer Institute
by Zacks Equity Research
We believe tie-ups like these will help PAREXEL (PRXL) drive its top and bottom line. The company also has a competitive edge in the Asia-Pacific markets.
Omnicell (OMCL) Gains on Product Launches, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) launches AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launches XT Series Automated Supply Dispensing system.
Exactech (EXAC) Truliant Knee System Receives IDEA Award
by Zacks Equity Research
Exactech (EXAC) has been leveraging on its Knee business. The Truliant Knee System is a notable platform in the Knee space, which offers an advanced approach to total knee replacement surgeries.
Here's Why Investors Should Buy Amedisys (AMED) Right Now
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Align Technology's Invisalign Sales Strong Amid Margin Woes
by Zacks Equity Research
Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.
LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space
by Zacks Equity Research
LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.
Accuray's Radixact Now Used by Boise Summit Cancer Center
by Zacks Equity Research
Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.
Globus Medical's Robotic Guidance System Gets FDA Approval
by Zacks Equity Research
Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
by Zacks Equity Research
LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.
Anika (ANIK) Grows in Orthopedic Medicines on Positive Data
by Zacks Equity Research
Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.
STERIS (STE) Banks on Organic Growth, Competition Intense
by Zacks Equity Research
STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.
Model N (MODN) Q3 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
Model N (MODN) reported narrower-than-expected loss in the third quarter driven by better customer acquisition.
Is a Surprise in Store for Penumbra (PEN) in Q2 Earnings?
by Zacks Equity Research
Penumbra's (PEN) escalating costs and expenses may keep margins under pressure in the yet-to-be-reported second quarter.
Top Stock Reports for Procter & Gamble, Altria & Bristol-Myers
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Altria (MO) and Bristol-Myers (BMY).
The Zacks Analyst Blog Highlights: McDonald's, 3M, Stryker, Goldman Sachs and Kinder Morgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McDonald???s, 3M, Stryker, Goldman Sachs and Kinder Morgan
Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More
by Zacks Equity Research
The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.
Why Earnings Season Could Be Great for Stryker Corporation (SYK)
by Zacks Equity Research
Stryker Corporation (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Top Stock Reports for McDonald's, 3M & Stryker
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), 3M (MMM), and Stryker (SYK).
Ecolab (ECL) to Report Q2 Earnings: Will It Pull a Surprise?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Ecolab's (ECL) growth in the second quarter.
Can Cerner (CERN) Deliver a Beat this Earnings Season?
by Zacks Equity Research
We believe Cerner's (CERN) strong sales performance, solid portfolio and strategic initiatives have positioned it for stellar growth.